• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

FDA Grants Authorisation for Minder®, the First and Only Implantable Continuous EEG Monitor Approved in US

PR Newswire by PR Newswire
22 April 2025
in PR Newswire
0
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter
  •  The Australian-developed Minder system is an implantable device for continuous monitoring of brain activity in patients with epilepsy, developed to address the shortcomings in current electroencephalogram technologies
  •  The FDA has granted authorisation for Minder under its De Novo pathway creating a new classification of device, allowing for marketing and sale of the device in the US for patients with drug resistant epilepsy
  •  Epiminder intends to launch Minder in the US during H2 2025

MELBOURNE, Australia and DALLAS, April 23, 2025 /PRNewswire/ — Epiminder, a pioneering medical device and information solutions company, today announced that it has been granted FDA authorisation via the De Novo classification for Minder, its proprietary implantable continuous electroencephalogram monitoring system (iCEMTM) for patients with epilepsy.  Minder has also been designated as a Breakthrough Technology by the FDA, recognising its potential to provide more effective diagnosis and management for people living with epilepsy. This De Novo authorization is significant as it creates a new classification of device which underscores both the innovation and the clinical validation behind Minder.

Without accurate diagnosis and monitoring, sustained and effective management of epilepsy can be challenging.  Minder has been developed to address the shortcomings in current electroencephalogram (EEG) technologies, providing reliable and actionable diagnostic data for more patients and therefore better enabling their prospects for successful epilepsy treatment. 

Rohan Hoare PhD, CEO of Epiminder, said: ” By extending the monitoring window of an EEG from days using current technologies to months or even years with Minder, we can deliver unprecedented access to a high-fidelity stream of continuous EEG data to health care professionals and their patients.

The FDA’s clearance of Minder is a significant milestone for Epiminder and more importantly for the 52 million people around the world who have epilepsy.  As the first and only implantable continuous EEG monitor approved in US, Minder can provide health care professionals and their patients with more accurate and timely diagnoses, enhanced therapeutic drug monitoring, and can better inform decisions on non-drug treatments like surgery.

Looking ahead, Epiminder plans to develop a suite of integrated software solutions that will extend the clinical impact of the Minder device, for example by providing patients with advance notice of seizures through AI-enabled forecasting.”

Epiminder intends to formally launch Minder in the US during H2 2025 undertaking a phased commercial roll out into leading epilepsy centres as part of a program to demonstrate the clinical utility of the system.

Professor Robert Fisher MD, PhD, Director of the Stanford Epilepsy Center, past-President of the American Epilepsy Society, and Chair of the Data Safety Monitoring Board for the UMPIRE trial, said: “One of the greatest difficulties in caring for people with epilepsy is the lack of accurate information about a patient’s seizures. Seizure diaries are of limited effectiveness. Minder can greatly improve seizure tracking and therefore seizure management. It will fill the significant gap in current EEG technologies, providing clinicians like me continuous and accurate data. By having a more complete picture, we can be more precise in our diagnoses, better able to rapidly adjust medication or neuromodulation regimens and identify patients for potential non-drug or surgical treatments. The result will be a reduction in the huge burden of drug resistant epilepsy.”

The safety and effectiveness of Minder was validated through Epiminder’s UMPIRE clinical study, a multi-centre prospective, open design, case-controlled comparator trial that was undertaken in leading Australian hospitals between 2019 and 2023.  The results of UMPIRE were used to support Epiminder’s successful FDA application.

Professor Mark Cook MD MBBS FRACP FRCP (London), Epiminder’s Founder and Chief Medical Officer, said: “The results from UMPIRE exceeded our expectations and demonstrated Minder’s ability to capture high-quality EEG data continuously for extended periods, including a groundbreaking five-year continuous recording in one participant.  Minder delivered actionable clinical insights for nearly 90 percent of study participants, highlighting the real-life benefits that Epiminder’s best-in-class iCEM can deliver relative to the current standard of care.”

Epilepsy is one of the most common serious chronic neurological disorders, affecting approximately 52 million people worldwide including 250,000 Australians and 3.4 million Americans. It is a neurological condition where a person experiences recurrent seizures caused by abnormal electrical activity in the brain.  Seizures can present with a variety of clinical manifestations; some involve motor symptoms, such as intense muscle contractions, while others, such as absence or focal impaired awareness seizures, may present with subtle or no outward physical signs.  The occurrence of seizures varies in frequency among patients, from less than one a year to several a day.

Follow Epiminder on LinkedIn and explore www.epiminder.com for more information.

About Minder

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder’s long-term monitoring of patients outside of a controlled clinical environment provides data needed for better understanding and more effective treatment of underlying conditions, including determining the effectiveness of drug therapies and other potential interventions.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited. Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

Contact: Matt Wright, matt@nwrcommunications.com.au

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

22 November 2026
DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

22 November 2026
  • Trending
  • Comments
  • Latest
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026

HK five-year plan offers UK long-term prospects: CE

10 November 2026
Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

19 November 2026

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026

Recent News

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com